Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Gynecologic Cancer

 

EC145 in Combination With Doxil® for Platinum Resistant Ovarian Cancer (7334)
Protocol EC-FV-06: A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (Pld/Doxil®/Caelyx®) In Combination Versus PLD In Participants with Platinum-Resistant Ovarian Cancer

Investigator: Barbara Ann Goff, MD;   Conditions: Ovarian Cancer;    Status: Closed;   Study ID: NCT01170650

Vaccine Therapy for Stage III-IV Ovarian Cancer (7396)
A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine Encoding the Amino Acids 1-163 of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in Patients With Advanced Ovarian Cancer

Investigator: Mary L. Disis, MD;   Conditions: Ovarian Cancer;    Status: Recruiting;   Study ID: NCT01322802

Chemotherapy + Pelvic Radiation for High-Risk Early-Stage Cervical Cancer (GOG/ RTOG 0724)
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy

Investigator: Benjamin Greer, MD;   Conditions: Cervical Cancer;    Status: Recruiting;   Study ID: NCT00980954

Combination Chemotherapy + Radiation Therapy for Stage III/IVA Endometrial Cancer (GOG 0258)
A Randomized Phase III Trialof Cisplatin and Tumor Volume Directional Irradiation Followed By Carboplatin and Paclitaxel Vs.for Optimally Debulked, Advanced Endometrial Carcinoma

Investigator: Benjamin Greer, MD;   Conditions: Endometrial Cancer;    Status: Recruiting;   Study ID: NCT00942357

Radiation vs Brachytherapy for Endometrial Carcinoma (GOG 249)
A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma

Investigator: Benjamin E. Greer, MD;   Conditions: Endometrial Cancer, Fatigue, Neurotoxicity;    Status: Recruiting;   Study ID: NCT00807768

Carboplatin + Paclitaxel w/wo Bevacizumab After Surgery (GOG 213)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination With Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreduction Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer

Investigator: Benjamin E. Greer, MD;   Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer;    Status: Recruiting;   Study ID: NCT00565851

Paclitaxel vs Polyglutamate Paclitaxel (GOG 212)
A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND# 70177), Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian or Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy

Investigator: Benjamin E. Greer, MD;   Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer;    Status: Recruiting;   Study ID: NCT00108745

MDX-1105 for Advanced or Recurrent Cancer (UW08038)
A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors

Investigator: Scott S. Tykodi, MD, PhD;   Conditions: Renal Cell Carcinoma, Non-small Cell Lung Cancer, Malignant Melanoma, Epithelial Ovarian Cancer;    Status: Recruiting;   Study ID: NCT00729664

MLN8237, an Aurora A Kinase Inhibitor w/ Weekly Paclitaxel (C14008).
Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer

Investigator: Barbara A. Goff, MD;   Conditions: Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Cancer, Breast Carcinoma;    Status: Closed;   Study ID: NCT01091428

FDG PET for Advanced Ovarian Cancer (FHCRC-7009)
FDG PET and Biomarkers in Treatment Response in Advanced Ovarian Cancer

Investigator: Dr. Joseph Rajendran;   Conditions: Advanced Ovarian Cancer;    Status: Recruiting

PARP Inhibitor ABT-888 with Carboplatin & Gemcitabline (M10-758) (UW09039)
A Phase 1 Study of ABT-888 (Veliparib) in Combination With Carboplatin (Paraplatin) and Gemcitabline (Gemzar) in Subjects With Advanced Solid Tumors

Investigator: Heidi J. Gray, MD;   Conditions: Advanced Solid Tumors;    Status: Closed;   Study ID: NCT01063816

Temsirolimus + Carboplatin/Paclitaxel Stage III-IV Clear Cell Carcinoma of the Ovary (GOG-0268)
A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC#683864, IND#61010) in Combination with Carboplatin and Paclitaxel followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary

Investigator: Benjamin Greer, MD;   Conditions: Ovarian Cancer;    Status: Recruiting;   Study ID: NCT01196429

Paclitaxel With or Without Pazopanib in Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer (GOG 186-J)
A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) (IND #75648) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

Investigator: Benjamin Greer, MD;   Conditions: Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cavity Cancer;    Status: Recruiting;   Study ID: NCT01468909

BIBF 1120 in Recurrent or Persistent Endometrial Cancer (GOG 229-K)
A Phase II Evaluation of BIBF 1120 (IND #) in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Investigator: Benjamin Greer, MD;   Conditions: Endometrial Cancer;    Status: Recruiting;   Study ID: NCT01225887

Memory and Thinking Skills Workshop in Improving Cognitive Rehabilitation in Ovarian Cancer Survivors (7750)
Behavioral and Neural Indices of Cognitive Rehabilitation in Ovarian Cancer: A Pilot Study

Investigator: Heidi J. Gray, MD;   Conditions: Ovarian Cancer;    Status: Recruiting;   Study ID: NCT01641068

Novel Markers to Predict Malignancy in Elevated-Risk Women (Novel Markers Trial--6973)
A Randomized Controlled Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women (Novel Markers Trial)

Investigator: Nicole Urban, Sc.D., ScD;   Conditions: Ovarian Cancer;    Status: Recruiting;   Study ID: NCT01121640

Rucaparib for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (CO-338-017)
A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Investigator: Elizabeth Swisher, MD;   Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer;    Status: Recruiting;   Study ID: NCT01891344

Cabozantinib or Paclitaxel Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (GOG -186K)
A Randomized Phase Ii Study Of Nci Supplied Cabozantinib (Nsc #761968 Ind #116059) Versus Weekly Paclitaxel (Nsc #673089) In The Treatment Of Persistent Or Recurrent Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Cancer

Investigator: Benjamin Greer, MD;   Conditions: Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer;    Status: Recruiting;   Study ID: NCT01716715

Radiation Therapy Stage I or Stage II Cervical Cancer Post Surgery (GOG 0263)
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy

Investigator: ;   Conditions: Cervical Cancer;    Status: Recruiting;   Study ID: NCT01101451

VTX-2337 + Pegylated Liposomal Doxorubicin (PLD) Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (GOG-3003)
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Investigator: Heidi J Gray, MD ;   Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer;    Status: Recruiting;   Study ID: NCT01666444

ID-LV305 for Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

Investigator: Seth M. Pollack, MD;   Conditions: Breast Cancer, Melanoma, Non-small Cell Lung Cancer, Ovarian Cancer, Sarcoma;    Status: Recruiting;   Study ID: NCT02122861

MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Recruiting;   Study ID: NCT01988896